Medical

Many lung cancer patients will be detected by genetic testing to carry an EGFR mutation, and these patients can often control their tumours with EGFR-targeted drugs. Although targeted drugs are effective and have fewer side effects than chemotherapy, resistance to them inevitably occurs, after which they no longer work.

Prostate cancer, which has been increasing in incidence worldwide in recent years, is now a more common cancer among Japanese men. Often, patients with prostate cancer have a poor prognosis and poor survival once they have developed multiple recurrent metastases after treatment with hormones and are difficult to treat with conventional radiotherapy.

Can patients with bridge onychiasis and hypothyroidism have normal childbearing?

Many women suffering from hyperthyroidism hope to become pregnant or have a second child, but hyperthyroidism is a chronic disease, which often cannot be cured for a long time. Many people mistakenly believe that hyperthyroidism and pregnancy are absolutely "incompatible" and "irreconcilable", which undoubtedly brings a lot of gloom to patients' family life.

New research confirms that the innovative treatment Zolbetuximab, in combination with chemotherapy, is highly effective in the treatment of gastric cancer, especially in advanced stages, and is expected to be a potential new treatment for patients with gastric cancer.

In recent years, scientists have begun to look at "transforming" cancer cells from life-threatening bad actors to help fight cancer.

With more and more new cutting-edge drugs emerging, the standard treatment paradigm for breast cancer is now rapidly changing, and the future is looking brighter for patients.

In our intestines, there are a wide variety of intestinal microorganisms, which are called intestinal microflora. Many studies have proved that they play an extremely important role in maintaining normal digestion and absorption, regulating immunity and preventing pathogen invasion.

Preoperative oxaliplatin-fluoropyrimidine chemotherapy given to colon cancer patients did not increase the risk of perioperative complications in colon cancer patients and did reduce postoperative recurrence rates, according to the results of the international phase 3/4 FOxTROT trial.

For patients with relapsed and refractory multiple myeloma, the CAR-T cell therapy Ide-cel resulted in a two-fold increase in the average length of time that patients' tumours did not progress compared to standard treatment, with 71% of patients experiencing substantial tumour regression and 39% experiencing complete tumour disappearance.